Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00884052




Registration number
NCT00884052
Ethics application status
Date submitted
17/04/2009
Date registered
20/04/2009
Date last updated
26/03/2020

Titles & IDs
Public title
Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures
Scientific title
Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures
Secondary ID [1] 0 0
Thrasher 02825-1
Universal Trial Number (UTN)
Trial acronym
Keppra
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Seizures 0 0
Disorder of Fetus or Newborn 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Low dose levetiracetam
Treatment: Drugs - High dose levetiracetam

No intervention: 2 - No exercise, twice weekly phone calls

Experimental: levetiracetam dose escalation - 6 Babies in Phase 1-Received Dose 1: 20 mg/kg; 5 mg/kg daily 12 Babies in Phase 2-Received Dose 2: 40 mg/kg; 10 mg/kg/day


Treatment: Drugs: Low dose levetiracetam
20 mg/kg loading dose; 5 mg/kg daily for 7 days.

Treatment: Drugs: High dose levetiracetam
40 mg/kg IV load; 10 mg/kg/day maintenance
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Drug Clearance
Timepoint [1] 0 0
Day 1 and Day 7

Eligibility
Key inclusion criteria
* Newborns admitted to the UCSD, Children's Hospital or Sharp Mary Birch NICUs with seizures.
* Term infants (gestational age greater than or equal to 37 weeks.
* > 2500 grams (max blood for study 6mL =3%).
* Postnatal age 14 days or less.
* Serum creatinine less than 1.2 at time of enrollment.
* Received loading dose of phenobarbital 20mg/kg.
* Are still experiencing either clinical or electroencephalographic seizures despite this therapy.
* For whom parental consent to participate in the study is obtained.
Minimum age
1 Minute
Maximum age
14 Days
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Biochemical abnormality - hypoglycemia, hypocalcemia-that when treated result in seizure cessation.
* Severe hypoxic ischemic injury likely to result in imminent death
* The only significant exclusions that will be made in recruitment and enrollment will be the exclusion of infants who are judged by the attending neonatologist to be so critically ill that death is imminent and benefit from neonatal intensive care is very unlikely.
* No rule-based criteria, (using lab or clinical parameters) adequately capture the complete nature of this clinical assessment.
* In general any child receiving active treatment with head cooling will not be excluded.
* Mechanical ventilation and/or the use of inotropic agents to support blood pressure will not be exclusion criteria.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/10/2011
Sample size
Target
Accrual to date
Final
18
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Primary sponsor type
Other
Name
Richard H. Haas
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The hypothesis is that a loading dose of 20 mg/kg and a maintenance dose of 5 mg/kg of Levetiracetam is going to be safe and effective in the treatment of seizures in neonates.
Trial website
https://clinicaltrials.gov/study/NCT00884052
Trial related presentations / publications
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed

Contacts
Principal investigator
Name 0 0
Richard Haas, MD
Address 0 0
University of Calfornia, San Diego
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00884052